SES Extends Global Reach of Microsoft Azure ExpressRoute with Multi-orbit Satellite Systems
9.9.2019 09:55:00 EEST | Business Wire | Press release
SES today announced it will provide dedicated, private network connectivity from any vessel, airplane, enterprise, energy or government site in the world to Microsoft Azure via its unique multi-orbit satellite systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190908005042/en/
SES Extends Global Reach of Microsoft Azure ExpressRoute with Multi-orbit Satellite Systems (Photo: Business Wire)
As a partner of Azure ExpressRoute, SES will provide global reach and fibre-like high-performance to Azure customers via its complete portfolio of Geostationary Earth Orbit (GEO) satellites, Medium Earth Orbit (MEO) O3b constellation, global gateway network, and core terrestrial network infrastructure around the world. SES will offer Azure customers opportunities to leverage its satellite-enabled managed services to connect locations and sites in rural, remote and underserved locations, as well as vessels and airplanes out at sea and in the skies that previously did not have access to cloud services.
In addition to its global fleet of over 50 GEO satellites, SES also delivers managed data services over its proven O3b MEO satellite system, the only successful non-geostationary orbit (NGSO) broadband constellation. SES’s 20 O3b satellites comprise the only operational system today that can deliver fibre-equivalent, MEF-certified data connectivity services, and certified cloud connectivity services. The systems’ intelligent GEO- and MEO- orbit resilience that facilitate edge compute capabilities are key enablers in the seamless integration of high-performance satellite connectivity into Microsoft’s and their customers’ sites.
In addition, Azure customers also will be able to tap into SES’s groundbreaking next-generation MEO communications system, O3b mPOWER. Launching in 2021, O3b mPOWER will deliver ten times the throughput of the existing O3b constellation with unprecedented flexibility and dynamic control to help drive global cloud adoption everywhere.
“We believe that the economic and productivity benefits of the cloud should be easily available to all enterprise, maritime and aeronautical customers as well as government organisations, regardless of location. Now, as a Microsoft Azure ExpressRoute connectivity partner, we are expanding our strategic collaboration with Microsoft and extending intelligent cloud and edge services from Azure to the most underserved end points on the planet,” said JP Hemingway, CEO of SES Networks. “As the only satellite network services provider to operate a global, multi-orbit fleet utilising an extensive fleet of GEO and MEO satellites, SES stands ready to help Azure customers connect to any site at cloud scale, supporting critical enterprise workloads and offering an end-to-end network solution for emerging AI, IoT, video content services, and future applications to come.”
Ross Ortega, Partner, Product Manager of Azure Networking, Microsoft Corp. said, “We are collaborating with SES across a range of initiatives to build upon their expertise in satellite communications and increase connectivity to critical services and applications for customers in remote and underserved areas. This new collaboration between SES and Microsoft Azure Express Route further enables us to bring Azure to any business or government site.”
SES also announced today an expanded collaboration with Microsoft to benefit from Azure’s extensive cloud and AI capabilities to deliver one of the first broadcast-grade cloud services for media delivery. This builds on the broader strategic work between SES and Microsoft, as well as their shared common vision to reach everyone with intelligent cloud, media and network solutions.
More information on Azure ExpressRoute Data Sheet available here.
Follow us on:
Social Media
Blog
Media Library
About SES
SES is the world’s leading satellite operator with over 70 satellites in two different orbits, Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). It provides a diverse range of customers with global video distribution and data connectivity services through two business units: SES Video and SES Networks. SES Video reaches over 355 million TV homes, through Direct-to-Home (DTH) platforms and cable, terrestrial, and IPTV networks globally. SES Video delivers a full suite of innovative end-to-end value-added services for both linear and digital distribution, and includes the ASTRA satellite system, which has the largest DTH television reach in Europe. SES Networks provides global managed data services, connecting people in a variety of sectors including telecommunications, maritime, aeronautical, and energy, as well as governments and institutions across the world. The SES Networks portfolio includes GovSat, a 50/50 public-private partnership between SES and the Luxembourg government, and O3b, the only non-geostationary system delivering fibre-like broadband services today. Further information is available at: www.ses.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190908005042/en/
Contact information
For further information:
Suzanne Ong
Public Relations
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom